<DOC>
	<DOCNO>NCT00003881</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody locate tumor cell either kill deliver tumor-killing substance without harm normal cell . Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining monoclonal antibody therapy chemotherapy may kill tumor cell . PURPOSE : Phase II trial study effectiveness monoclonal antibody trastuzumab plus carboplatin paclitaxel treat patient advance non-small cell lung cancer .</brief_summary>
	<brief_title>Trastuzumab Plus Chemotherapy Treating Patients With Advanced Non-small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : I. Assess toxicity monoclonal antibody HER2 carboplatin paclitaxel patient HER2 positive non-small cell lung cancer . II . Determine median time progression one year freedom progression patient population . III . Evaluate one year survival rate overall objective response rate patient population . OUTLINE : Patients receive paclitaxel IV 3 hour immediately follow carboplatin IV 30 minute immediately follow monoclonal antibody HER2 IV 30-90 minute day 1 . Patients also receive monoclonal antibody HER2 day 8 15 . Treatment repeat every 3 week 6 course . After 6 course treatment , patient may receive monoclonal antibody HER2 weekly 1 year absence disease progression unacceptable toxicity . Patients follow every 3 month 2 year , every 6 month 3 year year thereafter disease progression death . PROJECTED ACCRUAL : A total 22-44 patient accrue study .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm nonsmall cell lung cancer ( NSCLC ) Recurrent AND/OR Stage IIIB pleural pericardial effusion OR Stage IV Must least one bidimensionally measurable lesion Must HER2 positive ( 13+ ) Brain metastasis allow , symptom control require steroid Prior/Concurrent Therapy Biologic therapy : Not specify Chemotherapy : No prior chemotherapy NSCLC Endocrine therapy : No concurrent steroids Radiotherapy : At least 2 week since prior radiotherapy Surgery : Not specify PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 01 Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 1.5 mg/dL Transaminases great 5 time upper limit normal Renal : Creatinine great 2 mg/dL Cardiovascular : No uncontrolled angina pectoris arrhythmias No myocardial infarction within past 3 month No uncompensated congestive heart failure Ejection fraction least 45 % Other : No active infection Not pregnant nursing Fertile patient must use effective contraception HIV negative No active malignancy No evidence peripheral sensory neuropathy least grade 2</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2004</verification_date>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
</DOC>